News

Eric Jennings, MD, from Woolfson Eye Institute, discusses the SMARTCataract cloud-based app from Alcon and its implementation where he practices with David Hutton, Managing Editor, Ophthalmology Times.

According to the company, the acquisition will extend its leadership in ophthalmic medical devices market and expands its position in the vitreo-retinal surgery segment.

The research marks the first attempt at integrating a photoactivatable anti-angiogenic agent with a photosensitizer into a single nanoformulation for AMD treatment.

The case for treating keratoconus without waiting for disease progression

Glaukos Corp's iDose TR has received FDA approval for the reduction of IOP in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG) following a new drug application (NDA) submission.

Randomization has been completed and, according to the company, topline data is expected during the third quarter of 2024.

Umedaptanib pegol has potential to improve outcomes if used as a first-line medication prior to patients receiving treatments targeting VEGF.

The kidney and eye are structurally and functionally similar, and the diseases of the organs may present similarly and via common pathways.

Why “acceleration” is the industry keyword for 2024

According to the company, OCU410 is a modifier gene therapy product candidate being developed for dry AMD

Sblendorio brings decades of experience in the ophthalmic industry to his position on the Nanoscope board as the company continues to move forward in their commitment to retinal diseases.

Additional testing is needed to ensure accuracy across different groups.

LambdaVision seeks to cure genetic blindness with a protein-based artificial retina. Harnessing microgravity in low-Earth orbit, the company collaborates with NASA and the ISS to perfect its manufacturing process.

EXN407 has the potential to be the first topical treatment for diabetic retinopathy and diabetic macular oedema

The study results will help to identify dosing levels for future clinical trials

The partnership will further the effort to bring VGX-0111, a gene therapy treatment for AMD to patients and providers.

A Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser, the Eagle is intended for use in performing selective laser trabeculoplasty.

Ophthalmology witnessed a transformative year with 12 FDA approvals. As the year concludes, there remains a robust pipeline of drugs, setting high expectations for continued advancements in ophthalmological care in 2024 and beyond.

The study saw encouraging results and helped to identify suitable dosing levels for future clinical trials.

The company’s lead ophthalmology candidate, EXN407, has the potential to be the first topical treatment for diabetic macular edema.

The treatment option can have a positive impact on quality of life for patients.

The system hopes to use optical coherence tomography (OCT), while at the same time, leverage air and ultrasonic pulses to excite the mechanical waves in the cornea, enabling the detection of normotensive glaucoma.

Working smarter, not harder, to benefit patients

The company’s lead ophthalmology candidate, EXN407, has the potential to be the first topical treatment for DR/DME.

TP-03 (lotilaner ophthalmic solution, 0.25%) was approved by the FDA in 2023 under the brand name Xdemvy for the treatment of Demodex blepharitis and s being evaluated as an investigational therapy for the treatment of Meibomian Gland Disease (MGD) in patients with Demodex mites.

ROP can be a disease that affects both the retinal and choroidal vasculatures.

Both oxidative stress and HIF-1 have been previously implicated in the development of AMD.

Orbis advances cataract surgery training in low-resource areas with technology